30683-23-9

Usage

Chemical Properties

Light yellow Cryst

InChI:InChI=1/C6H4BrNO2/c7-4-2-1-3-8-5(4)6(9)10/h1-3H,(H,9,10)

Upstream product

• 55758-02-6 3-bromopyridine-2-carbonitrile 
• 10354-53-7 N-phenylpicolinamide 
• 188677-47-6 3-Bromo-pyridine-2-carboxylic acid phenylamide 

Downstream Products

• 53636-56-9 methyl 3-bromopicolinate 
• 1133854-55-3 N-allyl-N-benzyl-3-bromopicolinamide 
• 867353-49-9 3-bromo-N-methoxy-N-methylpyridine-2-carboxamide 
• 1254364-47-0 C₃₀H₃₆BBrN₄O₇ 
• 1338379-17-1 N-benzyl-3-bromo-2-pyridinecarboxamide 
• 1338379-20-6 (Z)-6-benzyl-5,7-dihydro-5-(phenylmethylene)-6H-pyrrolo[3,4-b]pyridin-7-one 
• 1261275-65-3 C₂₉H₂₃BrN₄O₃S 
• 1186038-19-6 5-(3-chlorophenylamino)benzo[f][1,7]naphthyridine-8-carboxylic acid 
• 434319-75-2 {2-[2-(cyclopropylmethylcarbamoyl)-pyridin-3-yl]benzyl}carbamic acid tert-butyl ester 
• 434319-48-9 {2-[2-(3-methylbutylcarbamoyl)pyridin-3-yl]benzyl}carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

GLUCOCORTICOID RECEPTOR MODULATOR AND METHODS OF USE

The present invention provides Compound (I): Compound (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising Compound (I) in combination with one or more pharmaceutically acceptable carriers, excipients, or diluents; and methods for the treatment of inflammatory and immune disorders comprising administering to a patient in need thereof an effective amount of Compound (I) or a pharmaceutically acceptable salt thereof.

An intra/intermolecular suzuki sequence to benzopyridyloxepines containing geometrically pure exocyclic tetrasubstituted alkenes

(Chemical Equation Presented) A route to enable the preparation of 5-benzylidenyl-benzopyridyloxepine analogues was developed to continue our research in the field of nuclear hormone receptor modulators. The key steps are1) a syn-stereoselective diboratio

Novel 3beta-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof

The invention concerns compounds of general formula 1, wherein: A, B, D and E represent one or two nitrogen atoms, the others being carbon atoms; X represents a S or, a O, thereby forming a bicyclic fused heteroaromatic, such as thieno[2,3-b]pyridine, furo[2,3-b]pyridine, thieno[3,2-b]pyridine, furo[3,2-b]pyridine, thieno[2,3-b]pyrazine, furo[2,3-b]pyrazine, thieno[2,3-c]pyridine, furo[2,3-c]pyridine, thieno[3,2-c]pyridine and furo[3,2-c]pyridine; R1 represents a linear or branched C1-C6 alkoxy group, a linear or branched C1-C6 alkylthio group; R2 represents a linear, branched, cyclic C2-C8 group, a 2- or 3- thienylmethyl group, or a benzyl group optionally substituted by one or several halogens, F, Cl, Br, I, C1-C4 alkyl, C1-C4 alkoxy, CF3, CN, NO2, OH; and their pharmaceutically acceptable salts. Said compounds are anti-dopaminergic agents.

Application of organolithium compounds in organic synthesis. Part 19. Synthetic strategies based on aromatic metallation. A concise regiospecific synthesis of 3-halogenated picolinic and isonicotinic acids

The synthesis of the halogenated picolin- and isonicotinalides (3) and (4) via metallation (n-BuLi) of the anilides (1) and (2) and then the reaction of the generated bis-lithiated anilides with halogenating agents (CCl3-CCl3, CH2Br-CH2Br, I2) followed by subsequent acidic hydrolysis of (3) and (4), as a way of regiospecific transformation of picoline and isonicotine acids into their C3-halogenated derivatives, is described.